Last reviewed · How we verify
Peginterferon Alfa
Peginterferon Alfa is a Interferon-alpha Small molecule drug developed by Third Affiliated Hospital, Sun Yat-Sen University. It is currently FDA-approved for Chronic hepatitis B, Chronic hepatitis C, Certain hematologic malignancies. Also known as: PEG-IFN, peginterferon alfa-2a or peginterferon alfa-2b.
Peginterferon alfa is an interferon-alpha protein conjugated with polyethylene glycol that activates innate and adaptive immune responses to suppress viral replication and inhibit cell proliferation.
Peginterferon alfa is an interferon-alpha protein conjugated with polyethylene glycol that activates innate and adaptive immune responses to suppress viral replication and inhibit cell proliferation. Used for Chronic hepatitis B, Chronic hepatitis C, Certain hematologic malignancies.
At a glance
| Generic name | Peginterferon Alfa |
|---|---|
| Also known as | PEG-IFN, peginterferon alfa-2a or peginterferon alfa-2b |
| Sponsor | Third Affiliated Hospital, Sun Yat-Sen University |
| Drug class | Interferon-alpha |
| Target | Interferon-alpha receptor (IFNAR) |
| Modality | Small molecule |
| Therapeutic area | Immunology, Virology, Oncology |
| Phase | FDA-approved |
Mechanism of action
Peginterferon alfa binds to interferon-alpha receptors on cell surfaces, triggering JAK-STAT signaling pathways that upregulate antiviral and antiproliferative genes. This leads to enhanced natural killer cell and cytotoxic T-lymphocyte activity, making it effective against chronic viral infections and certain malignancies. The pegylation extends the drug's half-life, allowing for less frequent dosing compared to unmodified interferon-alpha.
Approved indications
- Chronic hepatitis B
- Chronic hepatitis C
- Certain hematologic malignancies
Common side effects
- Flu-like symptoms (fever, fatigue, myalgia)
- Headache
- Neutropenia
- Thrombocytopenia
- Depression and psychiatric effects
- Thyroid dysfunction
- Injection site reactions
Key clinical trials
- Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma (PHASE2)
- A Phase 1 Study of MP-424, Peginterferon Alfa 2b, and Ribavirin in Hepatitis C (PHASE1)
- Nilotinib ± Peg-IFN for First Line Chronic Phase CML Patients (PHASE3)
- SOFIA-LTT Study: A Study of Intermittent Long Term Treatment With PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg Negative Chronic Hepatitis B (CHB). (PHASE2)
- A Follow-up Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B (NA)
- Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Participants With Chronic Hepatitis Delta (CHD) (PHASE2)
- Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection (PHASE2)
- A Study of Hepalatide Combined With TAF and PEG-IFN as Finite Treatment of Chronic Hepatitis B Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Peginterferon Alfa CI brief — competitive landscape report
- Peginterferon Alfa updates RSS · CI watch RSS
- Third Affiliated Hospital, Sun Yat-Sen University portfolio CI
Frequently asked questions about Peginterferon Alfa
What is Peginterferon Alfa?
How does Peginterferon Alfa work?
What is Peginterferon Alfa used for?
Who makes Peginterferon Alfa?
Is Peginterferon Alfa also known as anything else?
What drug class is Peginterferon Alfa in?
What development phase is Peginterferon Alfa in?
What are the side effects of Peginterferon Alfa?
What does Peginterferon Alfa target?
Related
- Drug class: All Interferon-alpha drugs
- Target: All drugs targeting Interferon-alpha receptor (IFNAR)
- Manufacturer: Third Affiliated Hospital, Sun Yat-Sen University — full pipeline
- Therapeutic area: All drugs in Immunology, Virology, Oncology
- Indication: Drugs for Chronic hepatitis B
- Indication: Drugs for Chronic hepatitis C
- Indication: Drugs for Certain hematologic malignancies
- Also known as: PEG-IFN, peginterferon alfa-2a or peginterferon alfa-2b
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing